NCT00307827 - Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Ulcerative Colitis

Interventions

DRUG

Visilizumab

Visilizumab administered intravenously once per day for two days

Trial Locations (16)

Site Reference ID/Investigator# 72334, Zagreb

Site Reference ID/Investigator# 71913, Manhasset

Site Reference ID/Investigator# 72366, Majadahonda (Madrid)

Site Reference ID/Investigator# 71894, Savannah

Site Reference ID/Investigator# 72345, Bologna

Site Reference ID/Investigator# 72314, Moscow

Site Reference ID/Investigator# 72315, Saint Petersburg

Site Reference ID/Investigator# 71953, Nizhny Novgorod

Site Reference ID/Investigator# 71897, Worcester

Site Reference ID/Investigator# 71895, Chapel Hill

Site Reference ID/Investigator# 71896, Cleveland

Site Reference ID/Investigator# 71875, Hamilton

Site Reference ID/Investigator# 71873, Winnipeg

Site Reference ID/Investigator# 72338, Osijek

Site Reference ID/Investigator# 72342, Saint Petersburg

Site Reference ID/Investigator# 72368, Badalona - Barcelona